During this time period, TDXD was covered by insurance for HER2-positive gastric or GOJ adenocarcinoma, with a history of receiving 2 or more previous therapies since 2020, TDXD was selected as 6th-line treatment. The gene discussed is ERBB2; the disease is adenocarcinoma.